Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

And yet, the key to saving these lives lies with the youth themselves. Patients have the best chance of survival when their ...

Dog immune diseases attack blood cells. A study found sick dogs have a critical immune imbalance: fewer immune system brake ...

KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly ...

Nektar Therapeutics' REZPEG shows progress in treating atopic dermatitis & alopecia areata. Click here to find out why I rate ...

HSPCs polarize in contact with bone marrow stromal cells constituting their niche. This study analyses the polarity of ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously treated gastric or gastro-esophageal junction cancer, according to a multicenter ...

Anktiva is designed to address BCG-unresponsive bladder cancer through its mechanism as an interleukin-15 superagonist.

T lymphocytes destroy compromised cells in the body and help to alert ... includes the external barriers of our body — the first line of defense against pathogens — such as the skin and ...

We describe two patients in whom malignant monoclonal T-cell ... in the first-line autograft apheresis product (Fig. S9 and Table S8). A skin-biopsy sample showed pleiomorphic lymphocytes with ...